Chosa (XSAT: CHOSA)

Last close As at 20/12/2024

SEK0.71

−0.02 (−2.74%)

Market capitalisation

SEK51m

Chosa Oncology (previously RhoVac) is a Danish biotech focused on the development of iCIP, a technology consisting of a cisplatin drug response predictor and a liposomal formulation of conventional cisplatin. iCIP has demonstrated encouraging clinical proof of concept from a Phase IIb study in breast cancer patients and Chosa is now looking for strategic partnerships to progress the clinical development of the technology.

Latest Insights

View More

Healthcare | Update

Chosa Oncology — Making headway in precision oncology

Healthcare | Update

RhoVac — On the home straight

Healthcare | Outlook

RhoVac — Phase IIb BRaVac study results in H122

Healthcare | Update

RhoVac — COVID-19 vaccines versus RV001

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Analyst

Key Management

  • Claus Frisenberg Pedersen

    CFO

  • Neil Goldsmith

    Chairman

  • Peter Buhl Jensen

    CEO

Research

Update

Healthcare

RhoVac — COVID-19 vaccines versus RV001

Update

Healthcare

RhoVac — Fast Track designation granted by FDA

Update

Healthcare

RhoVac — Limited impact from COVID-19 pandemic

Update

Healthcare

RhoVac — Phase IIb study progressing to plan

Update

Healthcare

RhoVac — Phase IIb BRaVac study enrolling patients

edison tv

Healthcare

Executive interview – RhoVac

Update

Healthcare

RhoVac — Funded to execute Phase IIb study as planned

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free